A phase 2/3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to Severely Active Ulcerative Colitis
|Effective start/end date||12/4/07 → 12/31/14|
- Janssen Biotech, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.